Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive hematologic malignancy characterized by drug resistance, relapse and poor prognosis. Chidamide, a histone deacetylase inhibitor, has shown epigenetic therapeutic potential in T-ALL, but its efficacy is limited and acquired drug resistance exists. To overcome these limitations, we systematically evaluated the synergistic Combination effects of three drug candidates, OTX-015 (BET inhibitor), Metformin (metabolic regulator), and Anlotinib (multitargeted tyrosine kinase inhibitor), with Chidamide. Overall design: The human T-ALL Jurkat cell line was treated under three conditions for 48 hours: 1) Chidamide (5 µM) alone, 2) Anlotinib (1 µM) alone, and 3) Combination of Chidamide (5 µM) and Anlotinib (1 µM). Untreated cells served as control. Total RNA was extracted from biological replicates for each group and subjected to RNA sequencing (RNA-seq) on an Illumina platform with 2×150 bp paired-end reads. Differential gene expression analysis was performed to identify genes and pathways modulated by the treatments.